tiprankstipranks
Trending News
More News >

Fusion Antibodies Secures Grant for Cancer Treatment Development

Story Highlights
  • Fusion Antibodies received a grant to develop a DR5 antibody for treatment-resistant cancers.
  • The project will enhance Fusion’s market positioning and demonstrate its scientific capabilities.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.

Fusion Antibodies Plc ( (GB:FAB) ) has shared an announcement.

Fusion Antibodies plc has received approval for a significant InnovateUK Launchpad grant, in collaboration with Queens University Belfast, to develop a humanised therapeutic DR5 antibody aimed at combating treatment-resistant cancers. The grant, totaling over £808k with up to £545k allocated to Fusion, will support the project over 18 months, covering labor, materials, and overheads. This initiative is expected to enhance Fusion’s market positioning by providing case study data for marketing its technologies and potentially licensing the therapeutic asset to third-party pharmaceutical companies, thereby demonstrating its scientific capabilities and strengthening its industry presence.

Spark’s Take on GB:FAB Stock

According to Spark, TipRanks’ AI Analyst, GB:FAB is a Neutral.

Fusion Antibodies Plc is facing substantial financial hurdles, with declining revenues and significant losses. Technical analysis indicates bearish momentum, and valuation metrics highlight unprofitability. Despite these challenges, recent corporate events, including successful fundraising and strategic collaborations, offer some optimism for future growth. However, the immediate financial health remains a primary concern, resulting in a low overall stock score.

To see Spark’s full report on GB:FAB stock, click here.

More about Fusion Antibodies Plc

Fusion Antibodies plc is a Belfast-based contract research organization specializing in pre-clinical antibody discovery, engineering, and supply for therapeutic drug and diagnostic applications. Established in 2001 as a spin-out from Queen’s University Belfast, the company offers a wide range of services including antibody generation, development, production, characterization, and optimization. Fusion Antibodies has successfully completed numerous projects and collaborates with major global pharmaceutical companies, aiming to expedite drug development processes through innovative platforms.

YTD Price Performance: -4.26%

Average Trading Volume: 944,836

Technical Sentiment Signal: Hold

Current Market Cap: £7.65M

Find detailed analytics on FAB stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App